Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GGT1 | P19440 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734695 | 0.85 | ACLY (0.48) | ACLYACACBACACATSHRALDH1A1 | |
| SCHEMBL16675253 | 0.82 | ACLY (0.35) | ACLYACACBACACATSHRALDH1A1 | |
| SCHEMBL16305064 | 0.81 | ACLY (0.57) | ACLYACACBACACATSHRCYP1A2 | |
| SCHEMBL16305062 | 0.81 | ACLY (0.57) | ACLYACACBACACATSHRCYP1A2 | |
| SCHEMBL16675250 | 0.78 | TSHR (0.35) | ACLYACACBACACATSHRALDH1A1 | |
| SCHEMBL16675245 | 0.76 | TSHR (0.33) | ACLYACACBACACATSHRALDH1A1 | |
| SCHEMBL320771 | 0.76 | ACLY (0.54) | ACLYACACBACACATSHRALDH1A1 | |
| SCHEMBL15012488 | 0.73 | ACLY (0.54) | ACLYACACBACACATSHRCYP1A2 | |
| SCHEMBL15012695 | 0.73 | ACLY (0.54) | ACLYACACBACACATSHRCYP1A2 | |
| SCHEMBL27782620 | 0.70 | ACLY (0.61) | ACLYACACBACACATSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637516-B2 | Betulinic acid proline derivatives as HIV inhibitors | HETERO RESEARCH FOUNDATION (IN) | 2017-05-02 | — | — | US | disclosed |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-11-26 | — | — | US | disclosed |
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | BET1, PGGT1B, RABGGTB | ACLY 2218/4885ACACB 1320/4885ACACA 850/4885 |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PELP1 | ACLY 2292/4885ACACB 2658/4885ACACA 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.